New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer ...

A proposed combination of Johnson & Johnson’s multiple myeloma bispecific Tecvayli has turned up positive trial data that ...

From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

One expert explains how bispecific antibodies are a ‘targeted and effective’ option for patients with multiple myeloma. Bispecific antibodies offer a “targeted and effective alternative” for the ...

Immune therapy linvoseltamab showed deep early responses in multiple myeloma, raising hopes some patients may avoid bone ...

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

Linvoseltamab demonstrated a 79% ORR in newly diagnosed multiple myeloma, with 86% in the 200 mg cohort, indicating robust efficacy. Rapid responses were observed, with a median time to partial ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...